Drew Moghanaki, Professor, Chief of Thoracic Oncology at the Department of Radiation Oncology and Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at David Geffen School of Medicine at UCLA, and Chief Medical Officer of Respirati, shared a post on X:
“Long-term results of the phase II TROG 15.03 FASTRACK II trial presented at ESTRO26 with simultaneous publication in The Lancet Oncology.”
Video: Long-term outcomes TROG 15.03 FASTRACK II: a multicentre, non-randomised, phase 2 study ESTRO26
Title: Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study
Authors: Shankar Siva, David Pryor, Jarad Martin, Nicholas Hardcastle, Daniel Moon, Prof Tomas Kron, Braden Higgs, Farshad Foroudi, Jeremy Ruben, Swetha Sridharan, Rebecca Montgomery, Ryan Davey, Charles Lin, Mark Shaw, Prof Nathan Lawrentschuk, Sree Appu, Ben G L Vanneste, Michael S Hofman, Declan G Murphy, Richard De Abreu Lourenco, Pascal Mancuso, Nicholas R Brook, Avi Raman, Lih-Ming Wong, Mark Sidhom, Simon Wood, Muhammad Ali, Mathias Bressel
Other articles featuring Drew Moghanaki on OncoDaily.
